Disc Medicine (IRON) Debt to Equity (2020 - 2022)

Disc Medicine (IRON) reported Debt to Equity of -$0.04 for Q2 2022, down 170.33% year-over-year from $0.05 in Q2 2021, and up 37.67% quarter-over-quarter from -$0.06 in Q1 2022.

Disc Medicine (IRON) Debt to Equity (2020 - 2022) Analysis & Trends

Disc Medicine (IRON) has 3 years of Debt to Equity data on file, last reported at -$0.04 in Q2 2022.

  • Debt to Equity for Q2 2022 came in at -$0.04, down 170.33% year-over-year; the trailing twelve-month figure through Jun 2022 was -$0.04 (down 170.33% YoY), and the FY2021 annual result was -$0.11, up 69.09% from the prior year.
  • Debt to Equity improved to -$0.04 in Q2 2022 per IRON's latest filing, from -$0.06 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.05 in Q1 2021 and troughed at -$0.35 in Q4 2020.
  • A 3-year average of -$0.06 and a median of -$0.04 in 2022 frame the typical range for Debt to Equity.
  • The sharpest annual moves came in 2021 and 2022: Debt to Equity surged 69.09% in 2021, then slumped 205.85% in 2022.
  • A 3-year view of Debt to Equity shows it stood at -$0.35 in 2020, then surged by 69.09% to -$0.11 in 2021, then jumped by 67.04% to -$0.04 in 2022.
  • Business Quant data shows IRON's Debt to Equity at -$0.04 in Q2 2022, -$0.06 in Q1 2022, and -$0.11 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.32
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Disc Medicine 2.73 Bn 2.00 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2022 -0.04
Mar 31, 2022 -0.06
Dec 31, 2021 -0.11
Sep 30, 2021 0.05
Jun 30, 2021 0.05
Mar 31, 2021 0.05
Dec 31, 2020 -0.35